['axial psoratic arthritis']
['secukinumab and placebo']

        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed

          -  Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic
             arthritis (CASPAR) criteria

          -  Active spinal disease defined by Bath ankylosing spondylitis disease activity index
             (BASDAI) score ≥ 4

          -  Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale)

          -  Inadequate Response to at least 2 non-steroidal anti-inflammatory drugs over a 4 weeks
             period

        Exclusion Criteria:

          -  History of exposure to other IL-17 or IL-23 inhibitor biologic drug

          -  History of exposure to previous biologic disease modifying anti-rheumatic drugs
             (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab)

          -  Current treatment with disease modifying anti-rheumatic drugs (DMARDs) other than
             Methotrexate

          -  Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone,
             morphine)

          -  Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing
             infectious or malignant process, obtained within 3 months prior to screening and
             evaluated by a qualified physician

        Other protocol-defined inclusion and exclusion criteria may have applied.
      